Chardan Capital Maintains Buy on Arrowhead Pharma, Raises Price Target to $80

Benzinga · 3d ago
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $60 to $80.